Each year, The Patient Story attends a handful of cancer conferences to meet with experts on the frontlines of cancer care and report on developments that matter to patients. We’ve reported on ASH, SABCS, and ASCO. The American Society for Clinical Oncology (ASCO), established in 1964, plays a pivotal role in the global fight against cancer. It was held from May 31 to June 4, 2024. This page provides updates from our attendance.
The American Society for Clinical Oncology (ASCO) and its annual meeting unites over 40,000 professionals from more than 100 countries across various oncology subspecialties and disciplines around the world, all committed to advancing cancer care. This premier organization is at the forefront of fostering innovative research, disseminating critical educational resources, and advocating for high-quality patient care. And we were there.
Using artificial intelligence support during HER2 testing can help pathologists identify HER2-low and HER2-ultralow breast cancers, reducing the rate of misclassifying these tumors
Maintenance therapy with lurbinectedin and atezolizumab helps patients with extensive-stage small cell lung cancer live longer
Molecular test may help identify non-small cell lung cancer patients who could benefit from chemotherapy after surgery
Combining ipilimumab and nivolumab before surgery, followed by selective adjuvant therapy, improves outcomes for stage III melanoma patients.
A combination of belantamab mafodotin, pomalidomide, and dexamethasone shows promise in treating relapsed or refractory multiple myeloma.
Sacituzumab govitecan helps some patients with PD-L1-positive triple-negative breast cancer live longer without cancer growth
Some advanced ovarian cancer patients may avoid lymph node removal during surgery safely.
Structured exercise program may lower risk of cancer recurrence and death for some colon cancer survivors
A new treatment combination cures classical Hodgkin lymphoma more effectively and with fewer side effects than intensive chemotherapy.
Targeted therapy drug asciminib is a safe and effective treatment for chronic phase chronic myeloid leukemia.
Targeted Drug Stops Lung Cancer Growth for Five Years in Over Half of People with Mutated Lung Cancer
Inavolisib can help people with previously treated HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation live longer
